Parsons Capital Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Parsons Capital Management’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-550	Closed	-$5K	–	358
2019 Q2	$5K	Hold	550	–	–	﹤0.01%	350
2019 Q1	$15K	Hold	550	–	–	﹤0.01%	344
2018 Q4	$12K	Hold	550	–	–	﹤0.01%	329
2018 Q3	$30K	Buy	+550	New	+$35.1K	﹤0.01%	352
2017 Q1	–	Sell	-550	Closed	-$44K	–	352
2016 Q4	$44K	Buy	+550	New	+$43.5K	0.01%	334
2015 Q2	–	Sell	-100	Closed	-$73K	–	555
2015 Q1	$73K	Buy	+100	New	+$75.1K	0.01%	425

Other funds holding TTPH

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Parsons Capital Management's TTPH Position: Q3 2019 in Review

Parsons Capital Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2019, closing a stake of 550 shares — an estimated $5K sold.

Parsons Capital Management first reported a position in TTPH in Q1 2015 and held it in 6 quarters. The position peaked at $73K in Q1 2015. 26 funds tracked by Wall St. Rank hold TTPH as of Q3 2019.

Parsons Capital Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Parsons Capital Management sold 550 Tetraphase Pharmaceuticals, Inc. shares in Q3 2019, an estimated $5K.
Parsons Capital Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2015 and held it in 6 quarters.
Parsons Capital Management's Tetraphase Pharmaceuticals, Inc. position peaked at $73K in Q1 2015.
26 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2019.

Based on Parsons Capital Management's 13F filing for Q3 2019, filed 12 Nov 2019.